Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

755
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
755
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

889
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
889

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clusters of postoperative endophthalmitis caused by non-tuberculous mycobacteria and Pseudomonas aeruginosa: diagnostic and sterilization challenges.

Journal of ophthalmic inflammation and infection·2026
Same author

Remission in sarcoid uveitis: identification of predictive factors.

The British journal of ophthalmology·2026
Same author

Impact of Different Intraocular Pressures During Cataract Surgery on Retinal Perfusion in Eyes with Diabetic Retinopathy: Randomized Clinical Trial.

Journal of cataract and refractive surgery·2026
Same author

Use of intravitreal fluocinolone acetonide implant in inflammatory macular oedema.

Eye (London, England)·2026
Same author

Results from a French brolucizumab access program for pretreated patients with neovascular age-related macular degeneration.

European journal of ophthalmology·2026
Same author

Long-term evolution of retinal atrophy after focal laser photocoagulation of telangiectatic capillaries: LyoMAC3 study.

Eye (London, England)·2025

Related Experiment Video

Updated: Oct 18, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.4K

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study.

Alper Bilgic1, Laurent Kodjikian2,3, Samaresh Srivastava4

  • 1Alphavision Augenarztpraxis Clinic, 27568 Bremerhaven, Germany.

Journal of Clinical Medicine
|September 28, 2021
PubMed
Summary

Pro re nata (PRN) intravitreal brolucizumab without a loading dose effectively improved vision in patients with neovascular age-related macular degeneration (AMD). This real-world study found no adverse events, demonstrating a safe and beneficial treatment option.

Keywords:
age-related macular degenerationanti-vascular endothelial growth factorbrolucizumabexudationtreatment-naive

More Related Videos

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.8K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.2K

Related Experiment Videos

Last Updated: Oct 18, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.4K
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.8K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.2K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Pharmacology

Background:

  • Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Current treatments often require frequent injections and loading doses.
  • Exploring alternative dosing regimens for intravitreal therapies is crucial for patient management.

Purpose of the Study:

  • To evaluate the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular AMD.
  • To assess treatment outcomes without a loading dose in a real-world setting.
  • To determine changes in visual acuity and retinal thickness.

Main Methods:

  • A retrospective, observational, multicentric study (PROBE study) was conducted.
  • 27 treatment-naïve patients with neovascular AMD received PRN brolucizumab.
  • Treatment intervals were at least 8 weeks; primary outcome was best-corrected visual acuity (BCVA) change.

Main Results:

  • Mean BCVA improved significantly from 57.4 to 65.3 letters (p=0.014), a gain of 7.8 letters.
  • Central subfield thickness (CST) significantly decreased (p=0.013).
  • Patients received an average of 2.2 additional injections during follow-up; no adverse events were reported.

Conclusions:

  • Initial PRN brolucizumab therapy without a loading dose is effective for exudative AMD.
  • This regimen demonstrated significant visual improvement and a favorable safety profile.
  • PRN brolucizumab offers a promising treatment option for neovascular AMD in real-world practice.